A Phase 3 interventional study of Pitavastatin and Atorvastatin in Type II Diabetes Mellitus and Dyslipidemia, sponsored by Kowa Research Europe. Completed at 35 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2010-02-23.
Sponsored by Kowa Research Europe (part of Kowa Company, Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 351 studies in Diabetes Mellitus, Type 2 with a site in Poland — 28 open to participants now, 38 under way, 22 of them phase 3. Diabetes Mellitus, Type 2 · Poland.
Among the 351 studies in Diabetes Mellitus, Type 2 with a site in Poland, this one is the 196th largest by enrollment of the 333 interventional ones that give a count, is one of 10 that started in 2005, is one of 218 in phase 3, and was the 20th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →28 of the 351 studies in Diabetes Mellitus, Type 2 with a site in Poland are open now. Recruiting first, the newest first:
Medical University of Bialystok · Sites in Poland
Ages 18–65
Ascletis Pharma (China) Co., Limited · Sites in Poland, United States, Czechia and 3 more countries
Ages 18+
Novo Nordisk A/S · Sites in Poland, United States, Argentina and 13 more countries
Ages 45+
AstraZeneca · Sites in Poland, United States, Argentina and 13 more countries
Ages 18+
Silesian Centre for Heart Diseases · Sites in Poland
Ages 35–75
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
351 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 67 · Phase 3 220 · Phase 4 28
First in 2001; this study’s year is marked. 10 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 418 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 500 across the 333 interventional studies, 3,039 across the 18 observational. Of the 307 that completed or were terminated, 203 (66%) have results posted.
This tab as a report to print or save as PDF → With an account.
335 of 351 have an industry lead sponsor. The 10 most frequent:
This study is registered under Kowa Research Europe, one of the names counted as Kowa Company, Ltd.. Under that name alone:
Kowa Research Europe is the lead sponsor of 10 studies on the registry; none are open to participants now.
Kowa Company, Ltd. has 5 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
10 of the studies in Diabetes Mellitus, Type 2 with a site in Poland that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06858878Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT07400653Phase 3PfizerA Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) | 2027-10-12 |
| NCT03811561Phase 3Novo Nordisk A/SA Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes | 2027-11-07 |
| NCT03604198Corcept TherapeuticsExtension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome | 2026-12 |
| NCT07606066AstraZenecaA Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies | 2027-03-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 351 studies in Diabetes Mellitus, Type 2 with a site in Poland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the efficacy and safety of pitavastatin with that of atorvastatin in patients with type II diabetes mellitus (type II DM) and combined dyslipidemia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Pitavastatin 4 mg once daily
Drug: Pitavastatin
Atorvastatin 20 mg once daily
Drug: Atorvastatin
Pitavastatin 4 mg QD
Atorvastatin 20 mg
Also known as: Lipitor
Percent Change From Baseline Low Density Lipoprotein Cholesterol (LDL-C)
Percent change from baseline to Week 12 low density lipoprotein cholesterol (LDL-C)
Time frame: 12 weeks
Number of Patients Attaining National Cholesterol Education Program (NCEP) LDL-C Target
Number of patients attaining National Cholesterol Education Program (NCEP)LDL-C target (LDL-C less than 160 mg/dL) at 12 weeks
Time frame: 12 weeks
| Milestone | Pitavastatin 4 mg QD | Atorvastatin 20 mg QD |
|---|---|---|
| Started | 279 | 139 |
| Safety population | 275 | 137 |
| Completed | 248 | 124 |
| Not completed | 31 | 15 |
Percent change from baseline to Week 12 low density lipoprotein cholesterol (LDL-C)
| percent change | Pitavastatin 4 mg QD | Atorvastatin 20 mg QD |
|---|---|---|
| Percent Change From Baseline Low Density Lipoprotein Cholesterol (LDL-C) | -40.78 ± 19.599 | -43.25 ± 16.378 |
Number of patients attaining National Cholesterol Education Program (NCEP)LDL-C target (LDL-C less than 160 mg/dL) at 12 weeks
| Participants | Pitavastatin 4 mg QD | Atorvastatin 20 mg QD |
|---|---|---|
| Number of Patients Attaining National Cholesterol Education Program (NCEP) LDL-C Target | 212 | 111 |
Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pitavastatin 4 mg QD | — | — | — |
| Atorvastatin 20 mg QD | — | — | — |
| Event | Pitavastatin 4 mg QD | Atorvastatin 20 mg QD |
|---|---|---|
| Non-cardiac chest painGeneral disorders | 0/275 | 1/137 |
| Alcohol poisoningInjury, poisoning and procedural complications | 0/275 | 1/137 |
| Humerus fractureInjury, poisoning and procedural complications | 0/275 | 1/137 |
| Intervertebral disc disorderMusculoskeletal and connective tissue disorders | 0/275 | 1/137 |
| Myocardial infarctionCardiac disorders | 1/275 | 0/137 |
| Tachycardia paroxysmalCardiac disorders | 1/275 | 0/137 |
| GastroenteritisInfections and infestations | 1/275 | 0/137 |
| Blood creatinine increasedInvestigations | 1/275 | 0/137 |
| Event | Pitavastatin 4 mg QD | Atorvastatin 20 mg QD |
|---|---|---|
| DiarrheaGastrointestinal disorders | 6/275 | 9/137 |
| NasopharyngitisInfections and infestations | 12/275 | 9/137 |
| MyalgiaMusculoskeletal and connective tissue disorders | 11/275 | 0/137 |
| HypertensionVascular disorders | 0/275 | 4/137 |
| Age, Categorical(Participants) | Pitavastatin 4 mg QD | Atorvastatin 20 mg QD | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 191 | 93 | 284 |
| >=65 years | 84 | 44 | 128 |
| Age Continuous(years) | Pitavastatin 4 mg QD | Atorvastatin 20 mg QD | Total |
|---|---|---|---|
| Mean | 59.1 ± 9.21 | 59.8 ± 9.06 | 59.4 ± 9.15 |
| Sex: Female, Male(Participants) | Pitavastatin 4 mg QD | Atorvastatin 20 mg QD | Total |
|---|---|---|---|
| Female | 120 | 59 | 179 |
| Male | 155 | 78 | 233 |
The record gives a start of Dec 2005, a primary completion of Jun 2007 and a completion of Jun 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2010, 2 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pitavastatin